{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Islet+Cell+Tumor&page=2",
    "query": {
      "condition": "Islet Cell Tumor",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Islet+Cell+Tumor&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T03:08:11.471Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06663072",
      "title": "Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Pancreatic Neuroendocrine Tumor"
      ],
      "interventions": [
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "177Lu-DOTATATE",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2024-12-13",
      "completion_date": "2026-11",
      "has_results": false,
      "last_update_posted_date": "2026-01-09",
      "last_synced_at": "2026-05-22T03:08:11.471Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06663072"
    },
    {
      "nct_id": "NCT00454363",
      "title": "Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gastrin-Producing Neuroendocrine Tumor",
        "Lung Carcinoid Tumor",
        "Metastatic Digestive System Neuroendocrine Tumor G1",
        "Multiple Endocrine Neoplasia Type 1",
        "Pancreatic Glucagonoma",
        "Pancreatic Insulinoma",
        "Pancreatic Polypeptide Tumor",
        "Recurrent Digestive System Neuroendocrine Tumor G1",
        "Recurrent Pancreatic Neuroendocrine Carcinoma",
        "Regional Digestive System Neuroendocrine Tumor G1",
        "Somatostatin-Producing Neuroendocrine Tumor"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pazopanib Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2007-03",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2020-04-03",
      "last_synced_at": "2026-05-22T03:08:11.471Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • Houston, Texas",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00454363"
    },
    {
      "nct_id": "NCT02595424",
      "title": "Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gastric Neuroendocrine Carcinoma",
        "Intestinal Neuroendocrine Carcinoma",
        "Pancreatic Neuroendocrine Carcinoma"
      ],
      "interventions": [
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "ECOG-ACRIN Cancer Research Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 67,
      "start_date": "2015-11-06",
      "completion_date": "2029-01-01",
      "has_results": true,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-05-22T03:08:11.471Z",
      "location_count": 673,
      "location_summary": "Kingman, Arizona • Phoenix, Arizona • Fort Smith, Arkansas + 431 more",
      "locations": [
        {
          "city": "Kingman",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Antioch",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02595424"
    },
    {
      "nct_id": "NCT03415139",
      "title": "Finding the Cause for Post-Transplant Diabetes Mellitus After Allogeneic Hematopoietic Cell Transplant",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetes Mellitus",
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Oral Glucose Tolerance Test (OGTT)",
          "type": "DRUG"
        },
        {
          "name": "2 OGTTs with and without GLP-1 analogue",
          "type": "DRUG"
        },
        {
          "name": "Hyperglycemic clamp procedure",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 120,
      "start_date": "2019-03-12",
      "completion_date": "2025-04",
      "has_results": false,
      "last_update_posted_date": "2022-03-28",
      "last_synced_at": "2026-05-22T03:08:11.471Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03415139"
    },
    {
      "nct_id": "NCT00004074",
      "title": "Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Adult Primary Liver Cancer",
        "Anaplastic Thyroid Cancer",
        "Bone Metastases",
        "Carcinoma of the Appendix",
        "Distal Urethral Cancer",
        "Fallopian Tube Cancer",
        "Gastrinoma",
        "Glucagonoma",
        "Inflammatory Breast Cancer",
        "Insulinoma",
        "Liver Metastases",
        "Localized Unresectable Adult Primary Liver Cancer",
        "Lung Metastases",
        "Male Breast Cancer",
        "Malignant Pericardial Effusion",
        "Malignant Pleural Effusion",
        "Metastatic Gastrointestinal Carcinoid Tumor",
        "Metastatic Parathyroid Cancer",
        "Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter",
        "Newly Diagnosed Carcinoma of Unknown Primary",
        "Occult Non-small Cell Lung Cancer",
        "Pancreatic Polypeptide Tumor",
        "Primary Peritoneal Cavity Cancer",
        "Proximal Urethral Cancer",
        "Pulmonary Carcinoid Tumor",
        "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity",
        "Recurrent Adrenocortical Carcinoma",
        "Recurrent Adult Primary Liver Cancer",
        "Recurrent Anal Cancer",
        "Recurrent Bladder Cancer",
        "Recurrent Breast Cancer",
        "Recurrent Carcinoma of Unknown Primary",
        "Recurrent Cervical Cancer",
        "Recurrent Colon Cancer",
        "Recurrent Endometrial Carcinoma",
        "Recurrent Esophageal Cancer",
        "Recurrent Extrahepatic Bile Duct Cancer",
        "Recurrent Gallbladder Cancer",
        "Recurrent Gastric Cancer",
        "Recurrent Gastrointestinal Carcinoid Tumor",
        "Recurrent Islet Cell Carcinoma",
        "Recurrent Malignant Testicular Germ Cell Tumor",
        "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity",
        "Recurrent Non-small Cell Lung Cancer",
        "Recurrent Ovarian Epithelial Cancer",
        "Recurrent Pancreatic Cancer",
        "Recurrent Parathyroid Cancer",
        "Recurrent Prostate Cancer",
        "Recurrent Rectal Cancer",
        "Recurrent Renal Cell Cancer",
        "Recurrent Salivary Gland Cancer",
        "Recurrent Small Intestine Cancer",
        "Recurrent Squamous Cell Carcinoma of the Larynx",
        "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Recurrent Squamous Cell Carcinoma of the Nasopharynx",
        "Recurrent Squamous Cell Carcinoma of the Oropharynx",
        "Recurrent Thyroid Cancer",
        "Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter",
        "Recurrent Urethral Cancer",
        "Recurrent Vaginal Cancer",
        "Recurrent Vulvar Cancer",
        "Skin Metastases",
        "Small Intestine Adenocarcinoma",
        "Somatostatinoma",
        "Stage III Adenoid Cystic Carcinoma of the Oral Cavity",
        "Stage III Adrenocortical Carcinoma",
        "Stage III Bladder Cancer",
        "Stage III Cervical Cancer",
        "Stage III Colon Cancer",
        "Stage III Endometrial Carcinoma",
        "Stage III Esophageal Cancer",
        "Stage III Follicular Thyroid Cancer",
        "Stage III Gastric Cancer",
        "Stage III Malignant Testicular Germ Cell Tumor",
        "Stage III Mucoepidermoid Carcinoma of the Oral Cavity",
        "Stage III Ovarian Epithelial Cancer",
        "Stage III Pancreatic Cancer",
        "Stage III Papillary Thyroid Cancer",
        "Stage III Prostate Cancer",
        "Stage III Rectal Cancer",
        "Stage III Renal Cell Cancer",
        "Stage III Salivary Gland Cancer",
        "Stage III Squamous Cell Carcinoma of the Larynx",
        "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage III Squamous Cell Carcinoma of the Nasopharynx",
        "Stage III Squamous Cell Carcinoma of the Oropharynx",
        "Stage III Vaginal Cancer",
        "Stage III Vulvar Cancer",
        "Stage IIIA Anal Cancer",
        "Stage IIIA Breast Cancer",
        "Stage IIIA Non-small Cell Lung Cancer",
        "Stage IIIB Anal Cancer",
        "Stage IIIB Breast Cancer",
        "Stage IIIB Non-small Cell Lung Cancer",
        "Stage IV Adenoid Cystic Carcinoma of the Oral Cavity",
        "Stage IV Adrenocortical Carcinoma",
        "Stage IV Anal Cancer",
        "Stage IV Bladder Cancer",
        "Stage IV Breast Cancer",
        "Stage IV Colon Cancer",
        "Stage IV Endometrial Carcinoma",
        "Stage IV Esophageal Cancer",
        "Stage IV Follicular Thyroid Cancer",
        "Stage IV Gastric Cancer",
        "Stage IV Mucoepidermoid Carcinoma of the Oral Cavity",
        "Stage IV Non-small Cell Lung Cancer",
        "Stage IV Ovarian Epithelial Cancer",
        "Stage IV Pancreatic Cancer",
        "Stage IV Papillary Thyroid Cancer",
        "Stage IV Prostate Cancer",
        "Stage IV Rectal Cancer",
        "Stage IV Renal Cell Cancer",
        "Stage IV Salivary Gland Cancer",
        "Stage IV Squamous Cell Carcinoma of the Larynx",
        "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IV Squamous Cell Carcinoma of the Nasopharynx",
        "Stage IV Squamous Cell Carcinoma of the Oropharynx",
        "Stage IVA Cervical Cancer",
        "Stage IVA Vaginal Cancer",
        "Stage IVB Cervical Cancer",
        "Stage IVB Vaginal Cancer",
        "Stage IVB Vulvar Cancer",
        "Thyroid Gland Medullary Carcinoma",
        "Unresectable Extrahepatic Bile Duct Cancer",
        "Unresectable Gallbladder Cancer",
        "Urethral Cancer Associated With Invasive Bladder Cancer",
        "WDHA Syndrome"
      ],
      "interventions": [
        {
          "name": "recombinant interleukin-12",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ABI-007/carboplatin/trastuzumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "1999-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-28",
      "last_synced_at": "2026-05-22T03:08:11.471Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004074"
    },
    {
      "nct_id": "NCT01980732",
      "title": "68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Carcinoid Tumors",
        "Islet Cell (Pancreatic NET)",
        "Other Neuroendocrine Tumors"
      ],
      "interventions": [
        {
          "name": "68Ga-DOTA TATE",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Andrei Iagaru",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2017-08-23",
      "last_synced_at": "2026-05-22T03:08:11.471Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01980732"
    },
    {
      "nct_id": "NCT03375320",
      "title": "Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Functioning Pancreatic Neuroendocrine Tumor",
        "Intermediate Grade Lung Neuroendocrine Neoplasm",
        "Locally Advanced Digestive System Neuroendocrine Neoplasm",
        "Locally Advanced Digestive System Neuroendocrine Tumor G1",
        "Locally Advanced Lung Neuroendocrine Neoplasm",
        "Locally Advanced Pancreatic Neuroendocrine Tumor",
        "Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm",
        "Low Grade Lung Neuroendocrine Neoplasm",
        "Lung Neuroendocrine Tumor",
        "Lung Neuroendocrine Tumor G2",
        "Metastatic Digestive System Neuroendocrine Neoplasm",
        "Metastatic Digestive System Neuroendocrine Tumor G1",
        "Metastatic Lung Neuroendocrine Neoplasm",
        "Metastatic Lung Neuroendocrine Tumor",
        "Metastatic Pancreatic Neuroendocrine Neoplasm",
        "Metastatic Pancreatic Neuroendocrine Tumor",
        "Metastatic Thymus Neuroendocrine Neoplasm",
        "Neuroendocrine Neoplasm",
        "Neuroendocrine Tumor",
        "Neuroendocrine Tumor G2",
        "Non-Functioning Pancreatic Neuroendocrine Tumor",
        "Pancreatic Serotonin-Producing Neuroendocrine Tumor",
        "Thymus Neuroendocrine Tumor",
        "Unresectable Digestive System Neuroendocrine Neoplasm",
        "Unresectable Digestive System Neuroendocrine Tumor G1",
        "Unresectable Lung Neuroendocrine Neoplasm",
        "Unresectable Pancreatic Neuroendocrine Neoplasm",
        "Unresectable Thymus Neuroendocrine Neoplasm"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Cabozantinib S-malate",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Placebo Administration",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "X-Ray Imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 298,
      "start_date": "2018-10-26",
      "completion_date": "2026-08-19",
      "has_results": true,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-05-22T03:08:11.471Z",
      "location_count": 433,
      "location_summary": "Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 290 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Kingman",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03375320"
    },
    {
      "nct_id": "NCT00428597",
      "title": "A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Carcinoma, Islet Cell",
        "Carcinoma, Pancreas"
      ],
      "interventions": [
        {
          "name": "sunitinib malate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 171,
      "start_date": "2007-06",
      "completion_date": "2009-04",
      "has_results": true,
      "last_update_posted_date": "2010-10-11",
      "last_synced_at": "2026-05-22T03:08:11.471Z",
      "location_count": 14,
      "location_summary": "Aurora, Colorado • Iowa City, Iowa • Worcester, Massachusetts + 6 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        },
        {
          "city": "City of Saint Peters",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00428597"
    },
    {
      "nct_id": "NCT00005910",
      "title": "Laparoscopy to Remove Pancreatic Tumors (Insulinomas)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Insulinoma"
      ],
      "interventions": [
        {
          "name": "Intraoperative ultrasound",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 23,
      "start_date": "2000-06",
      "completion_date": "2006-05",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-05-22T03:08:11.471Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005910"
    },
    {
      "nct_id": "NCT00005842",
      "title": "Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "trastuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "tipifarnib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2000-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-11",
      "last_synced_at": "2026-05-22T03:08:11.471Z",
      "location_count": 2,
      "location_summary": "Fort Sam Houston, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "Fort Sam Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005842"
    }
  ]
}